Emmalind Aponte, MD
Hematology & Oncology · San Antonio, TXNPI 1699985002
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,364 and has fallen 72.0% since, to $663 in 2025.
Across 174 payments — averaging $33.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$697
- Myriad Genetic Laboratories, Inc.$658
- AstraZeneca$509
- Takeda Pharmaceuticals U.S.A., Inc.$331
- Johnson & Johnson$316
- AbbVie$287
- plus $3K from 31 others
Across 931 payments — averaging $4689.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.2M
- Eli Lilly$785K
- Seagen Inc.$749K
- Genentech, Inc.$711K
- Merck$387K
- GSK$262K
- plus $298K from 9 others
What the payments were for
- Food & beverage$5,57096%
- Education$2284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 49 | $697 |
| Myriad Genetic Laboratories, Inc. | 5 | $658 |
| AstraZeneca(2 entities) | 10 | $509 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $331 |
| Johnson & Johnson(2 entities) | 15 | $316 |
| AbbVie | 6 | $287 |
| Amgen | 5 | $281 |
| Novartis | 14 | $222 |
| Gilead | 7 | $186 |
| Merck | 7 | $180 |
| Pfizer | 15 | $144 |
| Regeneron Healthcare Solutions, Inc. | 2 | $141 |
| Caris MPI, Inc. | 1 | $137 |
| Sanofi | 2 | $136 |
| Incyte Corporation | 2 | $131 |
| EMD Serono, Inc. | 1 | $126 |
| Bayer | 1 | $125 |
| Genmab U.S., Inc. | 1 | $125 |
| G1 Therapeutics, Inc. | 1 | $125 |
| Exelixis Inc. | 1 | $122 |
| Agios Pharmaceuticals, Inc. | 1 | $122 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $100 |
| Verastem, Inc. | 1 | $89 |
| Tesaro, Inc. | 1 | $88 |
| Lilly USA, LLC | 1 | $73 |
| Genentech USA, Inc. | 4 | $64 |
| Astellas Pharma US Inc | 3 | $45 |
| Tactile Systems Technology Inc | 2 | $33 |
| Boehringer Ingelheim | 2 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Clovis Oncology, Inc. | 2 | $26 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Array Biopharma Inc | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Medtronic | 1 | $15 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,798 in reported general payments places this provider in the 60th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 61 | $1,123,630 |
| TibsovoIvosidenib | 19 | $593,603 |
| PomalystPomalidomide | 23 | $574,005 |
| CabometyxCabozantinib S-Malate | 12 | $297,571 |
| OnuregAzacitidine | 11 | $280,438 |
| CalquenceAcalabrutinib Maleate | 18 | $276,600 |
| TasignaNilotinib Hcl | 13 | $242,081 |
| ErleadaApalutamide | 16 | $239,839 |
| KisqaliRibociclib Succinate | 15 | $233,752 |
| TagrissoOsimertinib Mesylate | 12 | $203,938 |
| Imatinib Mesylate | 32 | $51,582 |
| XareltoRivaroxaban | 41 | $39,567 |
| EliquisApixaban | 57 | $36,718 |
| Anastrozole | 409 | $5,071 |
| Ibandronate Sodium | 96 | $2,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg | $697 | $854,44334 claims |
| AstraZenecaCalquence, Tagrisso | $509 | $480,53830 claims |
| NovartisTasigna, Kisqali | $222 | $475,83328 claims |
| Exelixis Inc.Cabometyx | $122 | $297,57112 claims |
| Johnson & JohnsonErleada, Xarelto | $316 | $279,40657 claims |
| PfizerEliquis | $144 | $36,71857 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in San Antonio
- Timothy FenskeSan Antonio$626K
- Paul ShaughnessySan Antonio$470K
- Adolfo DiazSan Antonio$463K
- Francis GilesSan Antonio$436K
- John RenshawSan Antonio$430K
- Marcela Mazo-CanolaSan Antonio$257K
- Elizabeth Bowhay-CarnesSan Antonio$204K
- Nosha FarhadfarSan Antonio$117K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.